Protagenic Therapeutics, Inc.
PTIX
$0.218
-$0.0001-0.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -5.53M | -5.65M | -6.40M | -6.01M | -5.00M |
| Total Depreciation and Amortization | 50.40K | 64.40K | 53.20K | 40.70K | 28.20K |
| Total Amortization of Deferred Charges | -- | 10.20K | 35.70K | 60.90K | 85.80K |
| Total Other Non-Cash Items | 791.00K | 1.30M | 1.22M | 1.29M | 1.30M |
| Change in Net Operating Assets | 467.60K | -265.40K | 87.60K | -373.70K | -114.50K |
| Cash from Operations | -4.22M | -4.54M | -5.01M | -4.99M | -3.70M |
| Capital Expenditure | -- | -94.00K | -149.80K | -149.80K | -149.80K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2.80M | 5.17M | 5.82M | 5.83M | 4.93M |
| Cash from Investing | 2.80M | 5.08M | 5.67M | 5.68M | 4.78M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.96M | 361.50K | 44.50K | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.96M | 361.50K | 44.50K | -- | -- |
| Foreign Exchange rate Adjustments | 700.00 | 1.20K | 200.00 | 700.00 | 1.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 550.60K | 902.50K | 705.20K | 693.30K | 1.07M |